cimetidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H2-receptor antagonists, cimetidine derivatives 645 51481-61-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cimetidine
  • tagamet
  • tametin
  • ulcedin
  • ulcedine
  • ulcerex
  • ulcerfen
  • cimetidine hydrochloride
  • cimetidine HCl
A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
  • Molecular weight: 252.34
  • Formula: C10H16N6S
  • CLOGP: 0.38
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 88.89
  • ALOGS: -3.16
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O
0.80 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 6.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 62 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 158.51 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 16, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urine abnormality 148.19 13.68 58 14317 6641 56271051
Urine leukocyte esterase positive 121.32 13.68 41 14334 3087 56274605
Body tinea 116.26 13.68 33 14342 1387 56276305
Inhibitory drug interaction 99.96 13.68 33 14342 2311 56275381
Infection susceptibility increased 94.40 13.68 33 14342 2750 56274942
Lymphocyte count decreased 88.09 13.68 66 14309 27873 56249819
Glucose tolerance impaired 75.76 13.68 34 14341 5471 56272221
Culture urine positive 72.61 13.68 29 14346 3499 56274193
Rheumatoid arthritis 69.97 13.68 8 14367 382596 55895096
Urine ketone body present 68.58 13.68 25 14350 2352 56275340
Blood urine present 61.40 13.68 40 14335 13515 56264177
Purpura 60.66 13.68 36 14339 10326 56267366
Hyperlipidaemia 59.80 13.68 44 14331 18065 56259627
Impaired quality of life 59.11 13.68 33 14342 8441 56269251
Chronic kidney disease 57.53 13.68 62 14313 41994 56235698
Poor quality sleep 56.08 13.68 42 14333 17713 56259979
Drug intolerance 55.43 13.68 3 14372 264815 56012877
Bone density decreased 51.39 13.68 35 14340 12725 56264967
Anaphylactoid reaction 49.35 13.68 22 14353 3484 56274208
Erythema 43.82 13.68 112 14263 155827 56121865
Joint swelling 42.18 13.68 11 14364 289789 55987903
Neutrophil count increased 41.99 13.68 33 14342 14932 56262760
Impaired work ability 40.60 13.68 32 14343 14540 56263152
Torsade de pointes 36.14 13.68 28 14347 12412 56265280
Oral herpes 35.32 13.68 36 14339 22854 56254838
Band sensation 33.51 13.68 11 14364 756 56276936
Drug ineffective 33.31 13.68 122 14253 918867 55358825
Skin disorder 32.88 13.68 37 14338 26272 56251420
Bacterial test positive 31.02 13.68 18 14357 4950 56272742
Specific gravity urine decreased 29.81 13.68 10 14365 735 56276957
Product use issue 29.15 13.68 6 14369 186035 56091657
Tri-iodothyronine free decreased 28.78 13.68 8 14367 311 56277381
Hypertension 28.74 13.68 131 14244 244147 56033545
Creatinine urine decreased 27.93 13.68 7 14368 181 56277511
Keratitis 27.60 13.68 14 14361 2953 56274739
Infusion site scar 27.25 13.68 8 14367 379 56277313
Red cell distribution width increased 27.08 13.68 21 14354 9319 56268373
Urticaria 26.29 13.68 89 14286 144587 56133105
Infusion site discomfort 25.99 13.68 10 14365 1092 56276600
Circulatory collapse 25.55 13.68 29 14346 20774 56256918
Therapeutic product effect decreased 25.47 13.68 6 14369 169446 56108246
Cataract 24.95 13.68 46 14329 51201 56226491
Arthropathy 24.88 13.68 10 14365 200265 56077427
Cellulitis 24.39 13.68 57 14318 74892 56202800
Product dose omission issue 24.20 13.68 11 14364 204742 56072950
Anxiety 23.76 13.68 105 14270 193067 56084625
Contraindicated product administered 23.64 13.68 9 14366 186277 56091415
Electrocardiogram T wave amplitude decreased 23.52 13.68 7 14368 348 56277344
Insomnia 23.38 13.68 104 14271 191756 56085936
Wound 22.75 13.68 4 14371 138800 56138892
Systemic lupus erythematosus 22.35 13.68 9 14366 180069 56097623
Death 22.11 13.68 156 14219 341270 55936422
Red blood cells urine positive 21.95 13.68 12 14363 2944 56274748
Red blood cell count decreased 21.91 13.68 36 14339 36581 56241111
Blood thyroid stimulating hormone increased 21.78 13.68 16 14359 6547 56271145
Peripheral swelling 21.58 13.68 17 14358 234709 56042983
Protein urine present 21.51 13.68 15 14360 5661 56272031
Basophil count increased 21.05 13.68 8 14367 845 56276847
Alanine aminotransferase increased 21.02 13.68 62 14313 93600 56184092
White blood cell count decreased 20.71 13.68 75 14300 125915 56151777
Urobilinogen urine increased 20.24 13.68 6 14369 294 56277398
Nitrite urine present 19.59 13.68 8 14367 1021 56276671
Infusion site rash 19.29 13.68 9 14366 1583 56276109
Palmar-plantar erythrodysaesthesia syndrome 18.80 13.68 25 14350 21040 56256652
Maternal exposure during pregnancy 18.36 13.68 13 14362 189540 56088152
Flushing 18.28 13.68 49 14326 70051 56207641
Chromaturia 18.21 13.68 21 14354 15304 56262388
Food interaction 18.19 13.68 7 14368 765 56276927
Myelosuppression 17.59 13.68 22 14353 17433 56260259
Monocyte count decreased 17.51 13.68 9 14366 1951 56275741
Pancreatitis acute 16.81 13.68 26 14349 25098 56252594
Infusion site warmth 16.70 13.68 8 14367 1492 56276200
White blood cells urine positive 16.60 13.68 12 14363 4790 56272902
Thyroid cyst 16.38 13.68 6 14369 572 56277120
Hepatic enzyme increased 16.27 13.68 12 14363 171372 56106320
Feeling hot 16.09 13.68 34 14341 41753 56235939
Intentional product use issue 16.07 13.68 3 14372 99730 56177962
Red cell distribution width decreased 16.02 13.68 8 14367 1631 56276061
Abdominal discomfort 15.98 13.68 29 14346 277245 56000447
Blood creatinine decreased 15.82 13.68 12 14363 5154 56272538
Lower respiratory tract infection 15.49 13.68 5 14370 114789 56162903
Anion gap decreased 15.40 13.68 5 14370 332 56277360
Glucose urine present 15.27 13.68 6 14369 693 56276999
Arthralgia 14.73 13.68 72 14303 501597 55776095
pH urine increased 14.71 13.68 5 14370 383 56277309
Immune thrombocytopenia 14.60 13.68 15 14360 9610 56268082
Eosinophil count increased 14.58 13.68 15 14360 9622 56268070
Drug exposure before pregnancy 14.37 13.68 6 14369 810 56276882
Herpes zoster 14.05 13.68 47 14328 75842 56201850
Haematocrit increased 13.97 13.68 8 14367 2146 56275546
Platelet count decreased 13.96 13.68 59 14316 106324 56171368
Lactic acidosis 13.89 13.68 29 14346 35317 56242375

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 35.61 15.68 39 5707 37936 31653662
Renal injury 21.91 15.68 17 5729 10648 31680950
Mucosal erosion 20.14 15.68 7 5739 810 31690788
Palmar-plantar erythrodysaesthesia syndrome 18.28 15.68 18 5728 15465 31676133
Peptic ulcer 18.10 15.68 9 5737 2567 31689031
Decreased appetite 16.48 15.68 63 5683 153154 31538444
Adulterated product 16.15 15.68 3 5743 25 31691573

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urine abnormality 157.14 13.23 62 16836 7776 70903770
Urine leukocyte esterase positive 117.96 13.23 41 16857 3604 70907942
Body tinea 114.79 13.23 32 16866 1351 70910195
Lymphocyte count decreased 93.94 13.23 80 16818 43459 70868087
Infection susceptibility increased 90.85 13.23 32 16866 2925 70908621
Inhibitory drug interaction 90.16 13.23 34 16864 3773 70907773
Urine ketone body present 75.77 13.23 29 16869 3350 70908196
Culture urine positive 69.41 13.23 29 16869 4208 70907338
Glucose tolerance impaired 68.09 13.23 33 16865 6773 70904773
Impaired quality of life 56.95 13.23 32 16866 8884 70902662
Poor quality sleep 55.75 13.23 43 16855 20306 70891240
Bone density decreased 54.47 13.23 34 16864 11440 70900106
Hyperlipidaemia 53.83 13.23 45 16853 23818 70887728
Blood urine present 51.07 13.23 40 16858 19313 70892233
Purpura 49.27 13.23 38 16860 17937 70893609
Erythema 44.53 13.23 126 16772 199437 70712109
Anaphylactoid reaction 43.33 13.23 22 16876 4985 70906561
Rheumatoid arthritis 40.24 13.23 10 16888 291795 70619751
Hypertension 37.79 13.23 155 16743 295878 70615668
Torsade de pointes 36.45 13.23 32 16866 18084 70893462
Impaired work ability 35.18 13.23 30 16868 16310 70895236
Oral herpes 33.93 13.23 35 16863 24151 70887395
Red cell distribution width increased 33.40 13.23 27 16871 13630 70897916
Urticaria 32.57 13.23 99 16799 162950 70748596
Off label use 32.19 13.23 82 16816 742978 70168568
Band sensation 30.94 13.23 10 16888 702 70910844
Palmar-plantar erythrodysaesthesia syndrome 30.76 13.23 37 16861 30210 70881336
Joint swelling 30.68 13.23 11 16887 253200 70658346
Infusion site scar 29.69 13.23 8 16890 297 70911249
Specific gravity urine decreased 29.31 13.23 10 16888 831 70910715
Flushing 29.10 13.23 62 16836 82110 70829436
Skin disorder 29.04 13.23 36 16862 30321 70881225
Alanine aminotransferase increased 28.94 13.23 89 16809 147391 70764155
Chronic kidney disease 28.83 13.23 52 16846 61005 70850541
Keratitis 28.19 13.23 15 16883 3742 70907804
Tri-iodothyronine free decreased 28.09 13.23 8 16890 365 70911181
Red blood cell count decreased 27.99 13.23 47 16851 52114 70859432
Infusion site discomfort 27.74 13.23 10 16888 977 70910569
Bacterial test positive 26.42 13.23 18 16880 7013 70904533
Haematocrit increased 25.66 13.23 14 16884 3668 70907878
Monocyte count decreased 25.27 13.23 13 16885 3026 70908520
Insomnia 24.64 13.23 110 16788 217696 70693850
Drug ineffective 24.04 13.23 129 16769 939623 69971923
Cataract 23.28 13.23 45 16853 55600 70855946
Neutrophil count increased 22.82 13.23 30 16868 26765 70884781
White blood cell count decreased 22.40 13.23 90 16808 170051 70741495
Peptic ulcer 22.36 13.23 15 16883 5698 70905848
Gastrooesophageal reflux disease 21.86 13.23 59 16839 90780 70820766
Creatinine urine decreased 21.81 13.23 6 16892 241 70911305
Therapeutic product effect decreased 21.53 13.23 4 16894 143014 70768532
Infusion site rash 21.43 13.23 9 16889 1323 70910223
Basophil count increased 21.16 13.23 9 16889 1364 70910182
Ventricular tachycardia 21.13 13.23 34 16864 36389 70875157
Secondary adrenocortical insufficiency 21.08 13.23 11 16887 2636 70908910
Mean cell haemoglobin increased 20.61 13.23 12 16886 3561 70907985
Red cell distribution width decreased 19.68 13.23 9 16889 1620 70909926
Protein urine present 19.64 13.23 17 16881 9423 70902123
Dyspepsia 19.60 13.23 56 16842 89021 70822525
Contusion 19.54 13.23 71 16827 127965 70783581
Blood thyroid stimulating hormone increased 19.14 13.23 16 16882 8463 70903083
Infusion site warmth 19.13 13.23 8 16890 1163 70910383
Nitrite urine present 19.12 13.23 8 16890 1164 70910382
Therapeutic product effect incomplete 18.82 13.23 3 16895 119879 70791667
Peripheral swelling 17.86 13.23 18 16880 236545 70675001
White blood cells urine positive 17.85 13.23 13 16885 5627 70905919
Drug exposure before pregnancy 17.40 13.23 6 16892 515 70911031
Product dose omission issue 17.05 13.23 16 16882 217452 70694094
Anxiety 17.01 13.23 100 16798 220230 70691316
Aspartate aminotransferase increased 16.57 13.23 67 16831 126911 70784635
Leukocyturia 16.56 13.23 8 16890 1629 70909917
Electrocardiogram T wave amplitude decreased 16.51 13.23 6 16892 600 70910946
Infusion site pruritus 16.40 13.23 10 16888 3227 70908319
Eosinophil count increased 16.10 13.23 19 16879 15203 70896343
Urobilinogen urine increased 15.87 13.23 6 16892 670 70910876
Platelet count decreased 15.82 13.23 84 16814 178138 70733408
Arthropathy 15.80 13.23 8 16890 150049 70761497
Product use issue 15.62 13.23 12 16886 179925 70731621
Red blood cells urine positive 15.24 13.23 11 16887 4698 70906848
Circulatory collapse 15.22 13.23 29 16869 35445 70876101
Blood alkaline phosphatase increased 15.08 13.23 39 16859 58482 70853064
Thyroid cyst 14.93 13.23 5 16893 392 70911154
Blood creatinine decreased 14.82 13.23 13 16885 7336 70904210
Mean cell haemoglobin concentration increased 14.76 13.23 6 16892 812 70910734
Mucosal erosion 14.72 13.23 8 16890 2081 70909465
pH urine increased 14.48 13.23 5 16893 431 70911115
Contraindicated product administered 14.44 13.23 7 16891 134605 70776941
Cellulitis 14.37 13.23 54 16844 98874 70812672
Wound 14.36 13.23 3 16895 98729 70812817
Gamma-glutamyltransferase increased 14.34 13.23 35 16863 50650 70860896
Product use in unapproved indication 14.32 13.23 17 16881 207461 70704085
Blood lactate dehydrogenase increased 14.20 13.23 28 16870 35099 70876447
Food interaction 13.78 13.23 7 16891 1586 70909960
Duodenal ulcer haemorrhage 13.78 13.23 12 16886 6706 70904840
Coronary artery disease 13.37 13.23 39 16859 62697 70848849
Hepatic function abnormal 13.29 13.23 41 16857 67955 70843591

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BA01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
ATC A02BA51 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
FDA MoA N0000000151 Histamine H2 Receptor Antagonists
CHEBI has role CHEBI:37961 H2 receptor antagonists
CHEBI has role CHEBI:49201 anti-ulcer drugs
CHEBI has role CHEBI:50183 P450 inhibitors
CHEBI has role CHEBI:60809 adjuvants
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006635 Histamine H2 Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175784 Histamine-2 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Heartburn indication 16331000
Upper gastrointestinal hemorrhage indication 37372002
Duodenal ulcer disease indication 51868009 DOID:1724
Zollinger-Ellison syndrome indication 53132006 DOID:0050782
Multiple endocrine adenomas indication 60549007
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Systemic mast cell disease indication 397016004 DOID:349
Gastric ulcer indication 397825006 DOID:10808
Upper GI Bleed Prevention indication
Maintenance of Healing Duodenal Ulcer indication
Pancreatic insufficiency off-label use 37992001
Urticaria off-label use 126485001
Prevention of Stress Ulcer off-label use
NSAID-Induced Gastric Ulcer off-label use
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Malignant tumor of stomach contraindication 363349007 DOID:10534




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.83 acidic
pKa2 6.71 Basic
pKa3 0.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H2 receptor GPCR ANTAGONIST Kd 6.14 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.16 PDSP
Multidrug and toxin extrusion protein 1 Transporter IC50 5.92 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter INHIBITOR Ki 5.10 IUPHAR
Histamine H2 receptor GPCR Kd 6.58 CHEMBL
Histamine H2 receptor GPCR ANTAGONIST Ki 5.90 IUPHAR

External reference:

IDSource
4018845 VUID
N0000147147 NUI
D00295 KEGG_DRUG
70059-30-2 SECONDARY_CAS_RN
152402 RXNORM
4018844 VANDF
4018845 VANDF
C0008783 UMLSCUI
CHEBI:3699 CHEBI
CHEMBL30 ChEMBL_ID
CHEMBL1201051 ChEMBL_ID
DB00501 DRUGBANK_ID
D002927 MESH_DESCRIPTOR_UI
2756 PUBCHEM_CID
1231 IUPHAR_LIGAND_ID
3765 INN_ID
80061L1WGD UNII
101 MMSL
2261 MMSL
4448 MMSL
4449 MMSL
6098 MMSL
d00140 MMSL
003415 NDDF
004987 NDDF
373541007 SNOMEDCT_US
83051006 SNOMEDCT_US
83532008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8192 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8192 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8204 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8204 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8305 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0093-8305 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
Good Sense Heartburn Relief HUMAN OTC DRUG LABEL 1 0113-0022 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-0649 SOLUTION 300 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-0649 SOLUTION 300 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-1298 SOLUTION 400 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0121-1298 SOLUTION 400 mg ORAL ANDA 15 sections
cimetidineacid reducer HUMAN OTC DRUG LABEL 1 0363-0022 TABLET, FILM COATED 200 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0053 TABLET, FILM COATED 200 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0317 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0372 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0541 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 0440-1282 TABLET 400 mg ORAL ANDA 15 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-626 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-627 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-048 TABLET, FILM COATED 300 mg ORAL ANDA 17 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-265 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-372 TABLET, FILM COATED 800 mg ORAL ANDA 20 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 21695-531 TABLET 300 mg ORAL ANDA 14 sections
CIMETIDINE HUMAN PRESCRIPTION DRUG LABEL 1 21695-532 TABLET 400 mg ORAL ANDA 14 sections
Good Neighbor Pharmacy Heartburn Relief HUMAN OTC DRUG LABEL 1 24385-111 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Acid Reducer HUMAN OTC DRUG LABEL 1 30142-323 TABLET, FILM COATED 200 mg ORAL ANDA 16 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 33261-024 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 42291-217 TABLET, FILM COATED 300 mg ORAL ANDA 20 sections
Cimetidine HUMAN PRESCRIPTION DRUG LABEL 1 42291-218 TABLET, FILM COATED 400 mg ORAL ANDA 20 sections
Equate Cimetidine HUMAN OTC DRUG LABEL 1 49035-820 TABLET, FILM COATED 200 mg ORAL ANDA 15 sections